Clinical Trial: Phase 1 Study of APL-10456-Vaccine

U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399132) titled 'Phase 1 Study of APL-10456-Vaccine' on Jan. 27.

Brief Summary: AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers

Study Start Date: Feb. 09

Study Type: INTERVENTIONAL

Condition: Rhinovirus

Intervention: DRUG: APL-10456-Vaccine

3 cohorts are planned for Part A and Part B

OTHER: Placebo

Placebo (a saline) is comparator to study vaccine

Recruitme...